Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04592809). This is a study registration, not published results. Lead sponsor: University of Texas Southwestern Medical Center. Recruitment status: COMPLETED. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 50 participants (ACTUAL). Conditions: Suicide, Attempted, Suicide and Depression, Suicide Threat. Interventions: DRUG: Ketamine Hydrochloride; DRUG: Midazolam Hydrochloride. Primary outcome measures: Number of Days to First Suicidal Event , 12 weeks; Number of Days to First Suicidal Event (by Sex) , 12 weeks; Number of Days to First Suicidal Event (by Ethnicity) , 12 weeks; Number of Days to First Suicidal Event (by Race) , 12 weeks. Brief summary: This project aims to examine the signal of efficacy of ketamine, a rapidly acting medication shown to decrease suicidality in adults in as short as hours or days, as opposed to weeks. The study design is a double-blind, randomized, active-control trial of adolescents (ages 13-18 years) with recent suicidal behaviors (suicide attempt or increased suicidal ideation). All participants must be receiving standard of care treatment which may range broadly from both outpatient and inpatient programs which include clinically indicated psychosocial and/or psychopharmacological treatments. Ketamine/midazolam treatment will occur twice weekly during the first two weeks of the study, followed by weekly assessments through week 12.